News | Venous Therapies | April 26, 2017

VQI Varicose Vein Registry Yielding Data on Treatment Efficacy

Joint effort of the Society for Vascular Surgery and American Venous Forum was set up to track the outcomes of various treatments for varicose veins

April 26, 2017 — A new Varicose Vein Registry has begun producing useful outcomes information, as reported in the May edition of the Journal of Vascular Surgery: Venous and Lymphatic Disorders. The registry is a joint effort by the Society for Vascular Surgery, the Vascular Quality Initiative and the American Venous Forum. It was launched in January 2015 and was set up to track systematically the outcomes of various treatments for varicose veins, ultimately providing guidance for both consumers and treating physicians.

“The power in the registry resides in the ability to look at a large and varied data set with importantly defined and relevant physician-generated granular endpoints and patient-reported outcomes (PROs),” said Thomas Wakefield, M.D., who, with lead author Andrea Obi, M.D., developed the journal report.

The journal article, “First 10-month results of the Vascular Quality Initiative Varicose Vein Registry,” by a national team of vascular surgeons, examined the early data. The series included 1,406 patients undergoing venous ablations and phlebectomy. Overall, the reported outcomes were excellent, with significantly improved Clinical classification (CEAP) along with “much improved” Patient Reported Outcomes (PRO). Importantly, the complication rates including infection and venous thrombosis were 1 percent or less.

With governmental incentives for quality reporting, there is a pressing need for data in this evolving field, according to the societies. Although the database is in its early stages, they said it is clear it will bear important fruit for both patients and clinicians looking for the best, proven venous treatments available.

To download the complete article, click here.

For information patients may be interested in, click here.

For more information: www.jvsvenous.org

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...